| Characteristic |
Placebo (SD) |
Erythromycin (SD) |
P Value |
| Entry |
End |
Entry |
End |
| Weight z -score (kg) |
-1.8 ± 0.9 |
-0.9 ± 0.8 |
-1.6 ± 1.6 |
-1.7 ± 1.7 |
0.45 |
| Height z-score (cm) |
-1.7 ± 1.4 |
-1.6 ± 1.4 |
-1.7 ±1.5 |
-1.9 ± 1.4 |
0.97 |
| BMI z-score (kg/m2) |
-0.6 ± 0.9 |
-0.2 ± 1.0 |
-0.5 ± 1.3 |
-0.4 ± 1.6 |
0.08 |
| CD4 count (%) |
22.6 ± 11.9 |
29.3 ± 11.4 |
16.3 ± 6.7 |
21.7± 7.8 |
0.88 |
| CD4 (total×106) |
881.6 ± 505.8 |
939.3 ± 530.6 |
650.9 ± 446.7 |
1036.7 ± 461.8 |
0.47 |
| HIV viral load (copies/ml) |
80.0 ± 22514.3 |
0.0 ± 26685.9 |
0.0 ± 9635.2 |
0.0 ±19231.2 |
0.34 |
| FEV1 (% predicted) |
53.5 ± 13.6 |
62.5 ± 13.6 |
56.0 ± 15.1 |
68.0 ± 21.0 |
0.31 |
| FVC (% predicted) |
45.0 ± 14.3 |
58.0 ± 12.1 |
49.0 ±14.4 |
63.0 ±17.9 |
0.46 |
| IgG (g/ml) |
24.8 ± 15.4 |
22.7 ± 6.9 |
26.2 ± 8.4 |
19.0 ± 5.4 |
0.24 |
| CRP (mg/l) |
3.6 ± 16.1 |
2.4 ± 21.0 |
9.4 ± 18.8 |
4.0 ± 73.9 |
0.98 |
| Bhalla score |
11.5 ± 4.3 |
12.5 ± 4.1 |
15.0 ± 4.0 |
15.0 ± 3.30.62 |
|
Z-scores according to WHO growth charts [2,19]; CD4: cluster differentiation 4 cells; HIV: Human immunodeficiency virus; FEV1: Forced expiratory flow in 1 second;
FVC: Forced vital capacity; IgG: Immunoglobulin G; CRP: C-reactive protein. |
